182 related articles for article (PubMed ID: 28833358)
1. Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754).
Lin R; Hoerr DC; Weaner LE; Salter R
J Labelled Comp Radiopharm; 2017 Nov; 60(13):616-623. PubMed ID: 28833358
[TBL] [Abstract][Full Text] [Related]
2. Expeditious syntheses of stable and radioactive isotope-labeled anticonvulsant agent, JNJ-26990990, and its metabolites.
Lin R; Weaner LE; Hoerr DC; Salter R; Gong Y
J Labelled Comp Radiopharm; 2013 Jan; 56(1):22-6. PubMed ID: 24285137
[TBL] [Abstract][Full Text] [Related]
3. The syntheses of [
Maxwell BD
J Labelled Comp Radiopharm; 2017 Jun; 60(8):357-365. PubMed ID: 28273377
[TBL] [Abstract][Full Text] [Related]
4. Carbon 14 and Carbon 13 Syntheses of Velagliflozin.
Latli B; Hrapchak MJ; Chevliakov M; Shu C
J Labelled Comp Radiopharm; 2024 May; 67(5):180-185. PubMed ID: 38605481
[TBL] [Abstract][Full Text] [Related]
5. Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708.
Plesescu M; Elliott EL; Li Y; Prakash SR
J Labelled Comp Radiopharm; 2013; 56(9-10):464-70. PubMed ID: 24285522
[TBL] [Abstract][Full Text] [Related]
6. The synthesis of (14)C-labeled, (13)CD2-labeled saxagliptin, and its (13)CD2-labeled 5-hydroxy metabolite.
Tran SB; Maxwell BD; Cao K; Bonacorsi SJ
J Labelled Comp Radiopharm; 2014 Mar; 57(3):136-40. PubMed ID: 24519575
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic tumors in combination with radiotherapy.
Angelopoulou A; Kolokithas-Ntoukas A; Papaioannou L; Kakazanis Z; Khoury N; Zoumpourlis V; Papatheodorou S; Kardamakis D; Bakandritsos A; Hatziantoniou S; Avgoustakis K
Nanomedicine (Lond); 2018 Oct; 13(19):2435-2454. PubMed ID: 30311542
[TBL] [Abstract][Full Text] [Related]
8. GMP Compliant Synthesis of [
van der Hoek S; Antunes IF; Attia KA; Jacquet O; Heeres A; Bulthuis M; Zijlma R; Boersma HH; van Goor H; Visser TJ; Heerspink HJL; Elsinga PH; Stevens J
J Med Chem; 2021 Nov; 64(22):16641-16649. PubMed ID: 34748702
[TBL] [Abstract][Full Text] [Related]
9. β-Selective C-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups.
Henschke JP; Lin CW; Wu PY; Tsao WS; Liao JH; Chiang PC
J Org Chem; 2015 May; 80(10):5189-95. PubMed ID: 25909506
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
11. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol.
Fortuna D; McCloskey LJ; Stickle DF
Clin Chim Acta; 2016 Jan; 452():138-41. PubMed ID: 26569347
[TBL] [Abstract][Full Text] [Related]
12. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
[TBL] [Abstract][Full Text] [Related]
13. The syntheses of isotopically labelled CB-1 antagonists for the treatment of obesity.
Tran SB; Maxwell BD; Burrell R; Bonacorsi SJ
J Labelled Comp Radiopharm; 2016 Dec; 59(14):665-672. PubMed ID: 27624665
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological and clinical profile of a novel SGLT2 inhibitor canagliflozin hydrate (CANAGLU®)].
Kuriyama C; Ueta K; Arakawa K
Nihon Yakurigaku Zasshi; 2015 Dec; 146(6):332-41. PubMed ID: 26657125
[No Abstract] [Full Text] [Related]
15. Carbon-13 and carbon-14 labeled dabigatran etexilate and tritium labeled dabigatran.
Latli B; Kiesling R; Aßfalg S; Chevliakov M; Hrapchak M; Campbell S; Gonnella N; Busacca CA; Senanayake CH
J Labelled Comp Radiopharm; 2016 Dec; 59(14):648-656. PubMed ID: 27146196
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Shoda K; Tsuji S; Nakamura S; Egashira Y; Enomoto Y; Nakayama N; Shimazawa M; Iwama T; Hara H
Cell Mol Neurobiol; 2023 Mar; 43(2):879-892. PubMed ID: 35435536
[TBL] [Abstract][Full Text] [Related]
17. [Mode of SGLT inhibition by an SGLT2 inhibitor, canagliflozin and implication in renal and small intestinal effects].
Kuriyama C
Nihon Yakurigaku Zasshi; 2016; 148(5):245-252. PubMed ID: 27803437
[No Abstract] [Full Text] [Related]
18. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
19. Carbon-14 Labeling Synthesis of RORγt Inhibitor JNJ-61803534.
Song F; Salter R; Chen L
J Labelled Comp Radiopharm; 2024 Jun; 67(8):288-294. PubMed ID: 38803015
[TBL] [Abstract][Full Text] [Related]
20. Syntheses of (3) H-labeled, (14) C-labeled, and (2) H4 -labeled SCH 444877, phosphodiesterase type 5 inhibitors.
Ren S; Hesk D; McNamara P; Koharski D; Hendershot S
J Labelled Comp Radiopharm; 2013; 56(9-10):480-4. PubMed ID: 24285525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
